AIM

SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended September 30, 2005, for Hemispherx Biopharma, Inc. The company is a biopharmaceutical firm focused on immune system-enhancing technologies. Its primary assets include Ampligen(R), an experimental drug in Phase III trials for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and HIV, and Alferon N Injection(R), an FDA-approved treatment for genital warts. The company operates a GMP-certified manufacturing facility in New Jersey.

Key Financial Metrics

Note: All debt is classified as current as of September 30, 2005, due to maturity dates in late 2005 and early 2006.

Material Changes vs. Prior Period

• Reduced Net Loss: The net loss for the three months ended September 30, 2005, decreased by 59% compared to the prior year. This improvement was primarily driven by a $2.7 million reduction in non-cash financing charges related to convertible debentures and warrants.
• Revenue Mix: While total revenue increased slightly ($13,000), sales of Alferon N Injection(R) declined by 3%, offset by a 53% increase in revenue from Ampligen(R) cost-recovery clinical treatment programs.
• Production Costs: Production/cost of goods sold expenses dropped significantly ($606,000 decrease for the quarter) due to the absence of non-recurring facility ramp-up costs incurred in Q3 2004.
• Debt Structure: The company reclassified all long-term debt to current liabilities as the debentures matured in October 2005 and January 2006. Subsequent to the period end (October 6, 2005), the company amended these debentures to extend maturity to June 2007.

Guidance, Outlook, and Risks

• Regulatory Status: The FDA has requested a complete and audited report of the AMP 516 study to determine if Ampligen(R) treats a "serious or life-threatening" aspect of ME/CFS. The company intends to request a pre-NDA meeting but provides no guidance on the filing date or outcome.
• Manufacturing: The company signed a Letter of Intent with Hollister-Stier Laboratories for contract manufacturing of Ampligen(R). It is also building a raw material production line in New Brunswick, NJ, with an estimated total cost of $1.8 million.
• Liquidity: Management believes current cash and short-term investments ($11.6 million) plus proceeds from a common stock purchase agreement with Fusion Capital (up to $20 million) are sufficient for operations for the next 30 months. However, additional financing may be required.
• Risks: Key risks include the inability to secure FDA approval for Ampligen(R), failure to finalize manufacturing agreements, potential dilution from the Fusion Capital agreement, and ongoing litigation regarding alleged stock manipulation by a conspiratorial group.

Investor Verification Checklist

• Debt Maturity & Extension: Verify the terms of the October 6, 2005, amendment extending debenture maturity to 2007 and the issuance of new warrants.
• Fusion Capital Agreement: Review the conditions under which Fusion Capital is obligated to purchase stock (e.g., stock price must be above $1.00) and the potential for dilution.
• Manufacturing Transition: Confirm the status of the definitive agreement with Hollister-Stier and the timeline for the New Brunswick raw material facility.
• FDA Communication: Monitor for updates on the FDA's review of the AMP 516 study data and the schedule for the New Drug Application (NDA) submission.
• Litigation Status: Track the progress of the lawsuits filed against alleged conspiratorial groups attempting a hostile takeover.